Cargando…

Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition

PURPOSE: We aimed to enhance the solubility, dissolution rate, oral bioavailability, and α-glucosidase inhibition of glimepiride (Glm) by fabricating its nanosuspension using a precipitation–ultrasonication approach. METHODS: Glm nanosuspensions were fabricated using optimized processing conditions....

Descripción completa

Detalles Bibliográficos
Autores principales: Rahim, Haroon, Sadiq, Abdul, Khan, Shahzeb, Amin, Fazli, Ullah, Riaz, Shahat, Abdelaaty A, Mahmood, Hafiz Majid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689535/
https://www.ncbi.nlm.nih.gov/pubmed/31496686
http://dx.doi.org/10.2147/IJN.S210548
_version_ 1783443037676896256
author Rahim, Haroon
Sadiq, Abdul
Khan, Shahzeb
Amin, Fazli
Ullah, Riaz
Shahat, Abdelaaty A
Mahmood, Hafiz Majid
author_facet Rahim, Haroon
Sadiq, Abdul
Khan, Shahzeb
Amin, Fazli
Ullah, Riaz
Shahat, Abdelaaty A
Mahmood, Hafiz Majid
author_sort Rahim, Haroon
collection PubMed
description PURPOSE: We aimed to enhance the solubility, dissolution rate, oral bioavailability, and α-glucosidase inhibition of glimepiride (Glm) by fabricating its nanosuspension using a precipitation–ultrasonication approach. METHODS: Glm nanosuspensions were fabricated using optimized processing conditions. Characterization of Glm was performed using Malvern Zetasizer, scanning electron microscopy, transmission electron microscopy, differential scanning calorimetry, and powder X-ray diffraction. Minimum particle size and polydispersity index (PDI) values were found to be 152.4±2.42 nm and 0.23±0.01, respectively, using hydroxypropyl methylcellulose: 6 cPs, 1% w/v, polyvinylpyrrolidone K30 1% w/v, and sodium lauryl sulfate 0.12% w/v, keeping ultrasonication power input at 400 W, with 15 minutes' processing at 3-second pauses. In vivo oral bioavailability was assessed using rabbits as a model. RESULTS: The saturation solubility of the Glm nanosuspensions was substantially enhanced 3.14-fold and 5.77-fold compared to unprocessed drug in stabilizer solution and unprocessed active pharmaceutical ingredient. Also, the dissolution rate of the nanosuspensions ws substantially boosted when compared to the marketed formulation and unprocessed drug candidate. The results showed that >85% of Glm nanosuspensions dissolved in the first 10 minutes compared to 10.17% of unprocessed Glm), 42.19% of microsuspensions, and 19.94% of marketed tablets. In-vivo studies conducted in animals, i.e. rabbits, demonstrated that maximum concentration and AUC(0–24) with oral dosing were twofold (5 mg/kg) and 1.74-fold (2.5 mg/kg) and 1.80-fold (5 mg/kg) and 1.63-fold (2.5 mg/kg), respectively, and compared with the unprocessed drug formulation. In-vitro α-glucosidase inhibition results showed that fabricated nanosuspensions had a pronounced effect compared to unprocessed drug. CONCLUSION: The optimized batch fabricated by ultrasonication-assisted precipitation can be useful in boosting oral bioavailability, which may be accredited to enhanced solubility and dissolution rate of Glm, ultimately resulting in its faster rate of absorption due to nanonization.
format Online
Article
Text
id pubmed-6689535
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66895352019-09-06 Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition Rahim, Haroon Sadiq, Abdul Khan, Shahzeb Amin, Fazli Ullah, Riaz Shahat, Abdelaaty A Mahmood, Hafiz Majid Int J Nanomedicine Original Research PURPOSE: We aimed to enhance the solubility, dissolution rate, oral bioavailability, and α-glucosidase inhibition of glimepiride (Glm) by fabricating its nanosuspension using a precipitation–ultrasonication approach. METHODS: Glm nanosuspensions were fabricated using optimized processing conditions. Characterization of Glm was performed using Malvern Zetasizer, scanning electron microscopy, transmission electron microscopy, differential scanning calorimetry, and powder X-ray diffraction. Minimum particle size and polydispersity index (PDI) values were found to be 152.4±2.42 nm and 0.23±0.01, respectively, using hydroxypropyl methylcellulose: 6 cPs, 1% w/v, polyvinylpyrrolidone K30 1% w/v, and sodium lauryl sulfate 0.12% w/v, keeping ultrasonication power input at 400 W, with 15 minutes' processing at 3-second pauses. In vivo oral bioavailability was assessed using rabbits as a model. RESULTS: The saturation solubility of the Glm nanosuspensions was substantially enhanced 3.14-fold and 5.77-fold compared to unprocessed drug in stabilizer solution and unprocessed active pharmaceutical ingredient. Also, the dissolution rate of the nanosuspensions ws substantially boosted when compared to the marketed formulation and unprocessed drug candidate. The results showed that >85% of Glm nanosuspensions dissolved in the first 10 minutes compared to 10.17% of unprocessed Glm), 42.19% of microsuspensions, and 19.94% of marketed tablets. In-vivo studies conducted in animals, i.e. rabbits, demonstrated that maximum concentration and AUC(0–24) with oral dosing were twofold (5 mg/kg) and 1.74-fold (2.5 mg/kg) and 1.80-fold (5 mg/kg) and 1.63-fold (2.5 mg/kg), respectively, and compared with the unprocessed drug formulation. In-vitro α-glucosidase inhibition results showed that fabricated nanosuspensions had a pronounced effect compared to unprocessed drug. CONCLUSION: The optimized batch fabricated by ultrasonication-assisted precipitation can be useful in boosting oral bioavailability, which may be accredited to enhanced solubility and dissolution rate of Glm, ultimately resulting in its faster rate of absorption due to nanonization. Dove 2019-08-06 /pmc/articles/PMC6689535/ /pubmed/31496686 http://dx.doi.org/10.2147/IJN.S210548 Text en © 2019 Rahim et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Rahim, Haroon
Sadiq, Abdul
Khan, Shahzeb
Amin, Fazli
Ullah, Riaz
Shahat, Abdelaaty A
Mahmood, Hafiz Majid
Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition
title Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition
title_full Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition
title_fullStr Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition
title_full_unstemmed Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition
title_short Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition
title_sort fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689535/
https://www.ncbi.nlm.nih.gov/pubmed/31496686
http://dx.doi.org/10.2147/IJN.S210548
work_keys_str_mv AT rahimharoon fabricationandcharacterizationofglimepiridenanosuspensionbyultrasonicationassistedprecipitationforimprovementoforalbioavailabilityandinvitroaglucosidaseinhibition
AT sadiqabdul fabricationandcharacterizationofglimepiridenanosuspensionbyultrasonicationassistedprecipitationforimprovementoforalbioavailabilityandinvitroaglucosidaseinhibition
AT khanshahzeb fabricationandcharacterizationofglimepiridenanosuspensionbyultrasonicationassistedprecipitationforimprovementoforalbioavailabilityandinvitroaglucosidaseinhibition
AT aminfazli fabricationandcharacterizationofglimepiridenanosuspensionbyultrasonicationassistedprecipitationforimprovementoforalbioavailabilityandinvitroaglucosidaseinhibition
AT ullahriaz fabricationandcharacterizationofglimepiridenanosuspensionbyultrasonicationassistedprecipitationforimprovementoforalbioavailabilityandinvitroaglucosidaseinhibition
AT shahatabdelaatya fabricationandcharacterizationofglimepiridenanosuspensionbyultrasonicationassistedprecipitationforimprovementoforalbioavailabilityandinvitroaglucosidaseinhibition
AT mahmoodhafizmajid fabricationandcharacterizationofglimepiridenanosuspensionbyultrasonicationassistedprecipitationforimprovementoforalbioavailabilityandinvitroaglucosidaseinhibition